Trial Profile
A Single Centre, Three Part, Randomised, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Nemiralisib (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GSK
- 25 Jul 2018 Results published in the Clinical Therapeutics
- 09 Sep 2016 Status changed from recruiting to completed.
- 01 Mar 2016 New trial record